Finally, IDO inhibitors increased the survival of tumor-carrying mice when combined with anti-PD-1/anti-CTLA-4 antibodies, through the reduction in Treg in the TME and the increase in anti-tumor effector cells [122]. The gene discussed is PDCD1; the disease is neoplasm.